Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
about
Roles of MicroRNA across Prenatal and Postnatal PeriodsMolecular architecture of polycomb repressive complexesIdentification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, SDiscovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.Jarid2 binds mono-ubiquitylated H2A lysine 119 to mediate crosstalk between Polycomb complexes PRC1 and PRC2.The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.Polycomb repressive complex 2 in an autoinhibited state.Inhibitors of Protein Methyltransferases and Demethylases.EZH2 inhibitors: a patent review (2014-2016).Response to Comment on "Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2".Structure of the PRC2 complex and application to drug discovery.Recent progress in developing selective inhibitors of protein methyltransferases.Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.Developing EZH2-Targeted Therapy for Lung Cancer.The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells.Mrg15 stimulates Ash1 H3K36 methyltransferase activity and facilitates Ash1 Trithorax group protein function in Drosophila.Conserved RNA-binding specificity of polycomb repressive complex 2 is achieved by dispersed amino acid patches in EZH2.Chromatin modifying gene mutations in follicular lymphoma.Structure, mechanism, and regulation of polycomb repressive complex 2.Structures of human PRC2 with its cofactors AEBP2 and JARID2.Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2.Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors.Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins.Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin.Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2.Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2.Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells.An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors.Roles of H3K36-specific histone methyltransferases in transcription: antagonizing silencing and safeguarding transcription fidelity
P2860
Q28070336-F4CEF183-5FFE-4B48-A9E8-1BF34F0D74E5Q33364784-517D5446-5611-4AA2-94A7-08AE76FCEAE1Q33746209-9496A53E-34C5-44C3-A79B-11FC3F8FBC4CQ36245610-942E8AF2-4FBD-45D2-BC01-D6BF9BB90B65Q37465128-42CDC060-6B75-4812-8A0C-C2BFA1E7CC60Q38718857-2B7F3209-8065-4C25-966F-04803CDFA454Q38718859-5E5E9664-C362-4C20-94AB-8C312A590C39Q38728946-9C79B80F-A722-415F-A989-AAA95E537BA4Q38740496-69D14A87-68F4-439E-A277-5AB2DAE77440Q38844652-4D4324A1-E39F-4C7C-8408-06C9E46555BAQ39070262-14B8B949-AC17-4104-962E-C0F0AAD94F2CQ39245946-304FEA9C-C9FD-4BF9-B3FA-B28993415D45Q39405190-A02A2853-3C30-43CA-8554-064A9062B6A4Q39457118-0C4E5FFF-6573-44A6-A8F4-2C8B1EBCE0D9Q40968408-F263ED3D-B210-4D6F-BEB6-225F72A4CB50Q41021134-2EA9E1D6-D08A-4144-9840-F8EBD20B1799Q42366629-B775DF54-FC6E-4304-891B-DF24BB5B2B2EQ45754918-1811A2A1-4F22-4EF7-A19E-D8C6CD24F0B7Q46252089-B846C837-AD1F-4D51-BFD1-5695090BC9E2Q47828228-A42EC402-A78B-4B48-B3D4-966A4C37C564Q47948466-64102DC3-5355-4335-A655-58FBF44D0719Q48216200-2D763B79-8FA1-4778-B7ED-DA12AE0615C6Q48273323-8B08E681-BE98-4FA8-84B6-575277527D17Q48675669-572055FB-673E-4382-90D6-36A36AF7CE15Q49914122-C65C2AB1-788C-4227-B4E7-B4BD2814031DQ50022535-14610621-317A-4BF3-AB21-5412D4E7D90DQ52313298-5E46A9F1-3DE9-4B83-BA4C-35AB7A0555B9Q52313301-4902670E-3F76-41B6-A9F1-6F8F01E5A1DEQ52372471-D3470DFF-1D6F-479C-AC24-46A639126D6EQ52568730-63C2ADA4-D8E8-4C50-93D7-6C02C856824DQ55346934-B655ADC6-0F70-47AE-9A31-BB922BDCDEFCQ57498154-2E83690A-A9C0-42ED-A989-D1375AF3180D
P2860
Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Polycomb repressive complex 2 ...... activation and drug resistance
@nl
Polycomb repressive complex 2 ...... ctivation and drug resistance.
@ast
Polycomb repressive complex 2 ...... ctivation and drug resistance.
@en
type
label
Polycomb repressive complex 2 ...... activation and drug resistance
@nl
Polycomb repressive complex 2 ...... ctivation and drug resistance.
@ast
Polycomb repressive complex 2 ...... ctivation and drug resistance.
@en
prefLabel
Polycomb repressive complex 2 ...... activation and drug resistance
@nl
Polycomb repressive complex 2 ...... ctivation and drug resistance.
@ast
Polycomb repressive complex 2 ...... ctivation and drug resistance.
@en
P2093
P2860
P3181
P356
P1476
Polycomb repressive complex 2 ...... ctivation and drug resistance.
@en
P2093
Al E Stewart
Alexei Brooun
Ben Bolaños
Karen A Maegley
Ketan S Gajiwala
Nicole Grable
Patrick Bingham
Pei-Pei Kung
Scott Sutton
Wade Diehl
P2860
P2888
P3181
P356
10.1038/NCOMMS11384
P407
P577
2016-04-28T00:00:00Z
P6179
1004435065